-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 U+BHPPJAC7tllQ6sa0Mb0kDDlYQixMs//HXuqESWLGue6YhrQMASzjhBkyOi02C/
 Me1MfI+H5r9l5lurTDwJNw==

<SEC-DOCUMENT>0000910662-08-000448.txt : 20081028
<SEC-HEADER>0000910662-08-000448.hdr.sgml : 20081028
<ACCEPTANCE-DATETIME>20081028140928
ACCESSION NUMBER:		0000910662-08-000448
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20081028
FILED AS OF DATE:		20081028
DATE AS OF CHANGE:		20081028

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TRINITY BIOTECH PLC
		CENTRAL INDEX KEY:			0000888721
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22320
		FILM NUMBER:		081144368

	BUSINESS ADDRESS:	
		STREET 1:		IDA BUSINESS PARK, BRAY, CO WICKLOW
		STREET 2:		IRELAND
		CITY:			DUBLIN IRELAND
		STATE:			L2
		ZIP:			18
		BUSINESS PHONE:		01135312955111

	MAIL ADDRESS:	
		STREET 1:		3 ROCK ROAD
		STREET 2:		SANDYFORD INDUSTRIAL ESTATES
		CITY:			DUBLIN IRELAND
		STATE:			L2
		ZIP:			18
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>trinity6k1028.txt
<TEXT>
- --------------------------------------------------------------------------------


                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                             ----------------------


                                   F O R M 6-K

       REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
                   UNDER THE SECURITIES EXCHANGE ACT OF 1934

                         For the month of October, 2008

                               TRINITY BIOTECH PLC
                              (Name of Registrant)

                                IDA Business Park
                                Bray, Co. Wicklow
                                     Ireland

                     (Address of Principal Executive Office)

                  Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.

                           Form 20-F   X    Form 40-F __

                  Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):__

                  Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):__

                  Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
                                    Yes __ No X

                  If "Yes" is marked, indicate below the file number assigned to
the registrant in connection with Rule 12g3-2(b): 82-_______



================================================================================


<PAGE>


                               TRINITY BIOTECH PLC

6-K Item

         We hereby supplement our Report on Form 6-K dated October 7, 2008. As
reported, Mr. Brendan Farrell, on October 6, 2008, resigned with immediate
effect as CEO of the registrant. In addition, at the same time, Mr. Farrell also
resigned from his position as director of the registrant.

<PAGE>


                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


                                            TRINITY BIOTECH PLC
                                            -------------------
                                                (Registrant)


                                            By: /s/Kevin Tansley
                                                ----------------
                                                Kevin Tansley
                                                Chief Financial Officer


Date:  October 28, 2008




</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
